Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_assertion type Assertion NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_head.
- NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_assertion description "[A genetic predisposition for MRONJ, coupled with CYP 450 gene alterations, has been suggested to affect the degradation of medications for DM such as thiazolidinediones and may further increase the risk for MRONJ.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_provenance.
- NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_assertion evidence source_evidence_literature NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_provenance.
- NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_assertion SIO_000772 25477311 NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_provenance.
- NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_assertion wasDerivedFrom befree-2016 NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_provenance.
- NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_assertion wasGeneratedBy ECO_0000203 NP1245071.RAUqFzzeBHWPfco9vkjes9yfGPjXBsOnsjVI_JoLA-Gjw130_provenance.